Published in Archives

Lots of AMD news — Weekly Glance

This is editorially independent content
1 min read

Apellis Pharmaceuticals released 24-month data from the phase 3 OAKS and DERBY trials of its investigational treatment for geographic atrophy (GA).

The results from the trials showed that both monthly and every-other-month intravitreal injections of pegcetacoplan demonstrated a clinically meaningful reduction in GA lesion growth from baseline compared to sham.

Looking for a rundown on this drug? Read it here. (via)

Meanwhile, Iveric Bio is also working on a treatment for GA. The company recently announced positive topline results from GATHER2, its second phase 3 clinical trial of Zimura (avacincaptad pegol), a novel investigational complement C5 inhibitor.

GATHER2 met its prespecified primary endpoint of mean rate of growth (slope) in GA area at 12 months with statistical significance and a favorable safety profile. (via)

How would you rate the quality of this content?